Related Experiment Video
Updated: Nov 4, 2025

07:43
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.7K
Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
Martijn Beudel1, Fleur Rövekamp2, Diederik van de Beek2
1From the Department of Neurology (M. Beudel, D.v.d.B., M. Brouwer), Amsterdam Neuroscience Institute, Amsterdam University Medical Centers, the Netherlands; and Department of Neurology (F.R.), Northwest Hospitals, Alkmaar, the Netherlands. m.beudel@amsterdamumc.nl.
Neurology(R) Neuroimmunology & Neuroinflammation
|May 27, 2021
Summary
No abstract available in PubMed .
Related Concept Videos
Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Parkinson's Disease: Treatment
623
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
623

